This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Gilead Inks 10-Year Deal With Arcus for Immuno-oncology Drugs
by Zacks Equity Research
Gilead (GILD) looks to expand presence in the immune-oncology space with a 10-year partnership with Arcus.
Race for Coronavirus Vaccine Heats Up: Biotech ETFs to Gain
by Sweta Killa
The COVID-19 pandemic has kept biotech players all over the world on their toes for a vaccine. This new opportunity has made the sector the most attractive one to investors.
The Zacks Analyst Blog Highlights: Moderna, Pfizer, BioNTech, Sanofi and GlaxoSmithKline
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Moderna, Pfizer, BioNTech, Sanofi and GlaxoSmithKline
Coronavirus Vaccine Efforts Continue, Novavax Begins Human Trial
by Kinjel Shah
As several pharma/biotech companies speed up efforts to make a vaccine for COVID-19, Novavax (NVAX) begins human testing of its candidate, NVX-CoV2373.
Stocks & ETFs Beneficiaries of Coronavirus Vaccine Ramp-Up
by Sanghamitra Saha
Efforts in formulating a coronavirus vaccine are heating up. These stocks and ETFs look to be the largest beneficiaries.
Coronavirus Vaccine Development Gathers Steam: 4 Winners
by Ritujay Ghosh
Many biotech companies are coming up with impressive reports on their development of drugs, vaccines and therapies for COVID-19.
Profit from the Genomics Market Momentum With These ETFs
by Sweta Jaiswal, FRM
Here we highlight some ETFs for gaining exposure to the genomics market that is currently buzzing with opportunities for investors to cash on.
Gilead (GILD) Gains 13% YTD on Coronavirus Drug Development
by Zacks Equity Research
Gilead's experimental coronavirus drug, remdesivir, shows promise. The stock has been in news since the onset of the year on updates from the same.
Pharma Stock Roundup: FDA Ok's Cancer Drugs for New Use, JNJ Stops US Baby Powder Sales
by Kinjel Shah
FDA approves line extensions for Bristol-Myers (BMY), Roche (RHHBY) and AstraZeneca (AZN)/Merck's (MRK) drugs. J&J stops sales of talc-based baby powders in the United States and Canada.
Gilead, Galapagos Announce Positive Data on Inflammatory Drug
by Zacks Equity Research
Gilead (GILD) and Galapagos announce positive data on filgotinib for the treatment of ulcerative colitis.
Is Moderna Winning the COVID-19 Vaccine Race? ETFs to Gain
by Sweta Jaiswal, FRM
Moderna has presented positive interim data from a phase I study evaluating its mRNA-based coronavirus vaccine candidate.
AstraZeneca's Enhertu Gets Breakthrough Therapy Tag for NSCLC
by Zacks Equity Research
The FDA assigns a Breakthrough Therapy status to AstraZeneca's (AZN) Enhertu for treating patients with metastatic NSCLC whose tumors have a HER2 mutation.
Glaxo's Long-Acting HIV Injection Effective Than Daily Pills
by Zacks Equity Research
Glaxo's (GSK) long-acting injectable formulation of cabotegravir dosed every two months shows higher efficacy than daily oral pills.
Moderna Rallies on Encouraging Coronavirus Vaccine Study Data
by Zacks Equity Research
Moderna's (MRNA) coronavirus vaccine candidate achieves levels of antibodies similar or higher than those typically found in a patient who recovered from COVID-19 naturally.
5 Biotech Stocks in Focus as Race for Coronavirus Vaccine Heats Up
by Ritujay Ghosh
Drugmakers and biotech companies are initiating development of drugs, vaccines and therapies for COVID-19 and substantial progress has been made over the past month.
Here's Why Moderna (MRNA) Stock is Jumping Today
by Madeleine Johnson
On Monday, shares of biotech Moderna Inc. (MRNA) soared over 26% in midday trading, and closed up XX% to $X.
Clovis' (CLVS) Rubraca Gets FDA Approval for Prostate Cancer
by Zacks Equity Research
Clovis' (CLVS) PARP inhibitor, Rubraca, receives approval from the FDA as monotherapy to treat BRCA-mutant metastatic castration-resistant prostate cancer.
Pluralsight, Stanley Black Decker, Gilead, Regeneron and GlaxoSmithKline as Zacks Bull and Bear of the Day
by Zacks Equity Research
Pluralsight, Stanley Black Decker, Gilead, Regeneron and GlaxoSmithKline as Zacks Bull and Bear of the Day
Biotech Companies Lead Search for Coronavirus Vaccine: 4 Winners
by Zacks.com
Although a vaccine is yet to be developed, many companies have already started ramping up manufacturing process of the experimental vaccine candidates they are working on.
Novavax Soars on Coronavirus Vaccine Funding: ETFs to Gain
by Sweta Jaiswal, FRM
Novavax received funding for the coronavirus vaccine and also delivered better-than-expected Q1 results resulting in a stock rally in yesterday's trading session.
Mylan (MYL) Beats on Q1 Earnings on Coronavirus-Led Stockpiling
by Zacks Equity Research
Mylan (MYL) beats on Q1 earnings but misses on sales.
Theravance (TBPH) Q1 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
Theravance (TBPH) reports wider- than-expected loss in the first quarter of 2020 while sales beat estimates. The company reiterates 2020 outlook.
Clovis (CLVS) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Clovis (CLVS) reports first-quarter 2020 results. The company's sole marketed drug, Rubraca, drives revenues. Shares up.
Gilead (GILD) Q1 Earnings Top, Coronavirus Candidate in Focus
by Zacks Equity Research
Gilead (GILD) reports better-than-expected results for the first quarter but the uncertain outlook for the year dampens investors' hopes.
The Zacks Analyst Blog Highlights: Gilead Sciences, Pfizer, Sanofi, GlaxoSmithKline and Moderna
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead Sciences, Pfizer, Sanofi, GlaxoSmithKline and Moderna